Cysteamine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cysteamine" in English language version.

refsWebsite

Global rank English rank

17web.archive.org

1^st place

17nih.gov

4^th place

11doi.org

2^nd place

6semanticscholar.org

11^th place

8^th place

3medicines.org.uk

3,823^rd place

2,387^th place

3europa.eu

68^th place

117^th place

2fda.gov

447^th place

338^th place

1hres.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1books.google.com

3^rd place

1jaad.org

low place

1dermnetnz.org

7,563^rd place

5,361^st place

1dermatologytimes.com

low place

1nytimes.com

7^th place

books.google.com

Singer TP (1975). "Oxidative Metabolism of Cysteine and Cystine". In Greenberg DM (ed.). Metabolic pathways: Metabolism of sulfur compounds. Vol. 7 (3rd ed.). New York: Academic Press. p. 545. ISBN 9780323162081. Archived from the original on 7 June 2021. Retrieved 11 January 2017.

canada.ca

"Genetic disorders". Health Canada. 9 May 2018. Retrieved 13 April 2024.

dermatologytimes.com

Hilton L (14 October 2020). "Cysteamine cream, tranexamic acid mesotherapy reveal similar efficacy, different safety". Dermatology Times. Archived from the original on 29 June 2021. Retrieved 29 June 2021.

dermnetnz.org

"Cysteamine cream". DermNet NZ. Archived from the original on 29 June 2021. Retrieved 29 June 2021.

doi.org

Besouw M, Masereeuw R, van den Heuvel L, Levtchenko E (August 2013). "Cysteamine: an old drug with new potential". Drug Discovery Today. 18 (15–16): 785–792. doi:10.1016/j.drudis.2013.02.003. PMID 23416144.
Gahl WA, Thoene JG, Schneider JA (July 2002). "Cystinosis". The New England Journal of Medicine. 347 (2): 111–121. doi:10.1056/NEJMra020552. PMID 12110740.
Shams F, Livingstone I, Oladiwura D, Ramaesh K (10 October 2014). "Treatment of corneal cystine crystal accumulation in patients with cystinosis". Clinical Ophthalmology. 8: 2077–2084. doi:10.2147/OPTH.S36626. PMC 4199850. PMID 25336909.
Hsu C, Mahdi H, Pourahmadi M, Ahmadi S (April 2013). "Cysteamine cream as a new skin depigmenting product". Journal of the American Academy of Dermatology. 68 (4): AB189. doi:10.1016/j.jaad.2012.12.781. Retrieved 10 October 2021.
Grimes PE, Ijaz S, Nashawati R, Kwak D (February 2019). "New oral and topical approaches for the treatment of melasma". International Journal of Women's Dermatology. 5 (1): 30–36. doi:10.1016/j.ijwd.2018.09.004. PMC 6374710. PMID 30809577.
Mansouri P, Farshi S, Hashemi Z, Kasraee B (July 2015). "Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial". The British Journal of Dermatology. 173 (1): 209–217. doi:10.1111/bjd.13424. PMID 25251767. S2CID 21618233.
Mathe N, Balogun M, Yoo J (January 2021). "A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids)". Journal of Cosmetic Dermatology. 20 (1): 204–206. doi:10.1111/jocd.13755. PMID 32997864. S2CID 222163129.
Kasraee B, Mansouri P, Farshi S (February 2019). "Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula". Journal of Cosmetic Dermatology. 18 (1): 293–295. doi:10.1111/jocd.12837. PMID 30537063. S2CID 54481706.
Karrabi M, David J, Sahebkar M (January 2021). "Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study". Skin Research and Technology. 27 (1): 24–31. doi:10.1111/srt.12901. PMID 32585079. S2CID 220078010.
Shannon KM, Fraint A (September 2015). "Therapeutic advances in Huntington's Disease". Movement Disorders. 30 (11): 1539–1546. doi:10.1002/mds.26331. PMID 26226924. S2CID 31037666.
Mitchel EB, Lavine JE (November 2014). "Review article: the management of paediatric nonalcoholic fatty liver disease". Alimentary Pharmacology & Therapeutics. 40 (10): 1155–1170. doi:10.1111/apt.12972. PMID 25267322. S2CID 21263419.

europa.eu

ema.europa.eu

"Procysbi EPAR". European Medicines Agency (EMA). Archived from the original on 4 August 2020. Retrieved 27 April 2020.
"Cystagon EPAR". European Medicines Agency (EMA). Archived from the original on 11 November 2020. Retrieved 27 April 2020.
"Cystadrops EPAR". European Medicines Agency (EMA). Archived from the original on 4 August 2020. Retrieved 27 April 2020.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Cystaran (cysteamine) NDA #200740". U.S. Food and Drug Administration (FDA). 26 August 2013. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
"Drug Approval Package: PROCYSBI (cysteamine bitartrate) Delayed-Release Capsules NDA #203389". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 9 June 2020. Retrieved 9 June 2020.

hres.ca

pdf.hres.ca

"CYSTADROPS : Cysteamine Ophthalmic Solution" (PDF). Pdf.hres.ca. Archived (PDF) from the original on 10 June 2022. Retrieved 8 June 2022.

jaad.org

Hsu C, Mahdi H, Pourahmadi M, Ahmadi S (April 2013). "Cysteamine cream as a new skin depigmenting product". Journal of the American Academy of Dermatology. 68 (4): AB189. doi:10.1016/j.jaad.2012.12.781. Retrieved 10 October 2021.

medicines.org.uk

"Cystagon 150 mg hard capsules - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 19 June 2019. Archived from the original on 9 June 2021. Retrieved 28 April 2020.
"Cystadrops 3.8 mg/mL eye drops solution - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
"Procysbi 25 mg gastro-resistant hard capsules - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 17 September 2019. Archived from the original on 22 January 2021. Retrieved 9 June 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Besouw M, Masereeuw R, van den Heuvel L, Levtchenko E (August 2013). "Cysteamine: an old drug with new potential". Drug Discovery Today. 18 (15–16): 785–792. doi:10.1016/j.drudis.2013.02.003. PMID 23416144.
Gahl WA, Thoene JG, Schneider JA (July 2002). "Cystinosis". The New England Journal of Medicine. 347 (2): 111–121. doi:10.1056/NEJMra020552. PMID 12110740.
Nesterova G, Gahl WA (6 October 2016). "Cystinosis". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.). GeneReviews. Seattle WA: University of Washington. PMID 20301574. Archived from the original on 5 April 2011. Retrieved 11 January 2017.
Shams F, Livingstone I, Oladiwura D, Ramaesh K (10 October 2014). "Treatment of corneal cystine crystal accumulation in patients with cystinosis". Clinical Ophthalmology. 8: 2077–2084. doi:10.2147/OPTH.S36626. PMC 4199850. PMID 25336909.
Grimes PE, Ijaz S, Nashawati R, Kwak D (February 2019). "New oral and topical approaches for the treatment of melasma". International Journal of Women's Dermatology. 5 (1): 30–36. doi:10.1016/j.ijwd.2018.09.004. PMC 6374710. PMID 30809577.
Mansouri P, Farshi S, Hashemi Z, Kasraee B (July 2015). "Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial". The British Journal of Dermatology. 173 (1): 209–217. doi:10.1111/bjd.13424. PMID 25251767. S2CID 21618233.
Mathe N, Balogun M, Yoo J (January 2021). "A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids)". Journal of Cosmetic Dermatology. 20 (1): 204–206. doi:10.1111/jocd.13755. PMID 32997864. S2CID 222163129.
Kasraee B, Mansouri P, Farshi S (February 2019). "Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula". Journal of Cosmetic Dermatology. 18 (1): 293–295. doi:10.1111/jocd.12837. PMID 30537063. S2CID 54481706.
Karrabi M, David J, Sahebkar M (January 2021). "Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study". Skin Research and Technology. 27 (1): 24–31. doi:10.1111/srt.12901. PMID 32585079. S2CID 220078010.
Shannon KM, Fraint A (September 2015). "Therapeutic advances in Huntington's Disease". Movement Disorders. 30 (11): 1539–1546. doi:10.1002/mds.26331. PMID 26226924. S2CID 31037666.
Mitchel EB, Lavine JE (November 2014). "Review article: the management of paediatric nonalcoholic fatty liver disease". Alimentary Pharmacology & Therapeutics. 40 (10): 1155–1170. doi:10.1111/apt.12972. PMID 25267322. S2CID 21263419.

dailymed.nlm.nih.gov

"Cystagon- cysteamine bitartrate capsule". DailyMed. 29 January 2019. Archived from the original on 25 March 2021. Retrieved 27 April 2020.
"Cystaran- cysteamine hydrochloride solution". DailyMed. 22 November 2019. Archived from the original on 24 March 2021. Retrieved 27 April 2020.
"Procysbi- cysteamine bitartrate capsule, delayed release pellets Procysbi- cysteamine bitartrate granule, delayed release". DailyMed. U.S. National Library of Medicine. 23 March 2020. Archived from the original on 25 March 2021. Retrieved 27 April 2020.

ncbi.nlm.nih.gov

Nesterova G, Gahl WA (6 October 2016). "Cystinosis". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.). GeneReviews. Seattle WA: University of Washington. PMID 20301574. Archived from the original on 5 April 2011. Retrieved 11 January 2017.
Shams F, Livingstone I, Oladiwura D, Ramaesh K (10 October 2014). "Treatment of corneal cystine crystal accumulation in patients with cystinosis". Clinical Ophthalmology. 8: 2077–2084. doi:10.2147/OPTH.S36626. PMC 4199850. PMID 25336909.
Grimes PE, Ijaz S, Nashawati R, Kwak D (February 2019). "New oral and topical approaches for the treatment of melasma". International Journal of Women's Dermatology. 5 (1): 30–36. doi:10.1016/j.ijwd.2018.09.004. PMC 6374710. PMID 30809577.

nytimes.com

Pollack A (30 April 2013). "F.D.A. Approves Raptor Drug for Form of Cystinosis". The New York Times. Archived from the original on 10 September 2021. Retrieved 26 February 2017.

semanticscholar.org

api.semanticscholar.org

Mansouri P, Farshi S, Hashemi Z, Kasraee B (July 2015). "Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial". The British Journal of Dermatology. 173 (1): 209–217. doi:10.1111/bjd.13424. PMID 25251767. S2CID 21618233.
Mathe N, Balogun M, Yoo J (January 2021). "A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids)". Journal of Cosmetic Dermatology. 20 (1): 204–206. doi:10.1111/jocd.13755. PMID 32997864. S2CID 222163129.
Kasraee B, Mansouri P, Farshi S (February 2019). "Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula". Journal of Cosmetic Dermatology. 18 (1): 293–295. doi:10.1111/jocd.12837. PMID 30537063. S2CID 54481706.
Karrabi M, David J, Sahebkar M (January 2021). "Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study". Skin Research and Technology. 27 (1): 24–31. doi:10.1111/srt.12901. PMID 32585079. S2CID 220078010.
Shannon KM, Fraint A (September 2015). "Therapeutic advances in Huntington's Disease". Movement Disorders. 30 (11): 1539–1546. doi:10.1002/mds.26331. PMID 26226924. S2CID 31037666.
Mitchel EB, Lavine JE (November 2014). "Review article: the management of paediatric nonalcoholic fatty liver disease". Alimentary Pharmacology & Therapeutics. 40 (10): 1155–1170. doi:10.1111/apt.12972. PMID 25267322. S2CID 21263419.

web.archive.org

"CYSTADROPS : Cysteamine Ophthalmic Solution" (PDF). Pdf.hres.ca. Archived (PDF) from the original on 10 June 2022. Retrieved 8 June 2022.
"Cystagon 150 mg hard capsules - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 19 June 2019. Archived from the original on 9 June 2021. Retrieved 28 April 2020.
"Cystadrops 3.8 mg/mL eye drops solution - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
"Procysbi 25 mg gastro-resistant hard capsules - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 17 September 2019. Archived from the original on 22 January 2021. Retrieved 9 June 2020.
"Cystagon- cysteamine bitartrate capsule". DailyMed. 29 January 2019. Archived from the original on 25 March 2021. Retrieved 27 April 2020.
"Cystaran- cysteamine hydrochloride solution". DailyMed. 22 November 2019. Archived from the original on 24 March 2021. Retrieved 27 April 2020.
"Procysbi- cysteamine bitartrate capsule, delayed release pellets Procysbi- cysteamine bitartrate granule, delayed release". DailyMed. U.S. National Library of Medicine. 23 March 2020. Archived from the original on 25 March 2021. Retrieved 27 April 2020.
"Procysbi EPAR". European Medicines Agency (EMA). Archived from the original on 4 August 2020. Retrieved 27 April 2020.
"Cystagon EPAR". European Medicines Agency (EMA). Archived from the original on 11 November 2020. Retrieved 27 April 2020.
"Cystadrops EPAR". European Medicines Agency (EMA). Archived from the original on 4 August 2020. Retrieved 27 April 2020.
Singer TP (1975). "Oxidative Metabolism of Cysteine and Cystine". In Greenberg DM (ed.). Metabolic pathways: Metabolism of sulfur compounds. Vol. 7 (3rd ed.). New York: Academic Press. p. 545. ISBN 9780323162081. Archived from the original on 7 June 2021. Retrieved 11 January 2017.
Nesterova G, Gahl WA (6 October 2016). "Cystinosis". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.). GeneReviews. Seattle WA: University of Washington. PMID 20301574. Archived from the original on 5 April 2011. Retrieved 11 January 2017.
"Cysteamine cream". DermNet NZ. Archived from the original on 29 June 2021. Retrieved 29 June 2021.
Hilton L (14 October 2020). "Cysteamine cream, tranexamic acid mesotherapy reveal similar efficacy, different safety". Dermatology Times. Archived from the original on 29 June 2021. Retrieved 29 June 2021.
"Drug Approval Package: Cystaran (cysteamine) NDA #200740". U.S. Food and Drug Administration (FDA). 26 August 2013. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
"Drug Approval Package: PROCYSBI (cysteamine bitartrate) Delayed-Release Capsules NDA #203389". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
Pollack A (30 April 2013). "F.D.A. Approves Raptor Drug for Form of Cystinosis". The New York Times. Archived from the original on 10 September 2021. Retrieved 26 February 2017.